Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Vitamin D deficiency is shockingly common in cancer patients — and it may be costing lives. About two-thirds of cancer patients have insufficient vitamin D levels, even including many already taking supplements. Experts from MD Anderson are calling for routine 25(OH)D screening at cancer diagnosis and key treatment transitions, backed by growing evidence linking sufficient levels to better survival and fewer immunotherapy side effects.
Vitamin D deficiency is alarmingly common among cancer patients — and it's largely going undetected. Roughly two-thirds of patients with cancer have serum vitamin D levels below the recommended threshold of 30 ng/mL, and nearly one-third of those already taking supplements still fall short. Oncologists from MD Anderson Cancer Center are now making a strong case for routine screening of 25-hydroxyvitamin D (25[OH]D) at diagnosis and at key treatment transitions, paired with targeted supplementation for those found deficient.
The biological rationale is compelling: vitamin D receptor activation has been shown to induce cancer cell apoptosis, inhibit tumor growth, and potentially synergize with chemotherapy and immunotherapy. Clinical data back this up — a prospective cohort of nearly 4,000 breast cancer patients found that sufficient vitamin D levels were linked to significantly better overall and disease-free survival. The PROVIDENCE study found that vitamin D supplementation in patients on immune checkpoint inhibitors improved overall survival and cut thyroid-related adverse events by 84%.
Key Takeaways:
Why it matters: Vitamin D screening is low-cost, low-risk, and increasingly evidence-backed — making it one of the most actionable integrative strategies available to oncology teams today.
